CoChat
Sign Up
Cited by 313

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n‐3 and n‐6 polyunsaturated fatty acids

Arendt, Bianca M., Comelli, Elena M., Ma, David W.L., Lou, Wendy, Teterina, Anastasia, Kim, TaeHyung, Fung, Scott K., Wong, David K.H., McGilvray, Ian, Fischer, Sandra E., Allard, Johane P.·2015·Hepatology
DOI 10.1002/hep.27695
Open this paper in CoChat — free account

Abstract

In nonalcoholic fatty liver disease, hepatic gene expression and fatty acid (FA) composition have been reported independently, but a comprehensive gene expression profiling in relation to FA composition is lacking. The aim was to assess this relationship. In a cross‐sectional study, hepatic gene expression (Illumina Microarray) was first compared among 20 patients with simple steatosis (SS), 19 with nonalcoholic steatohepatitis (NASH), and 24 healthy controls. The FA composition in hepatic total lipids was compared between SS and NASH, and associations between gene expression and FAs were examined. Gene expression differed mainly between healthy controls and patients (SS and NASH), including genes related to unsaturated FA metabolism. Twenty‐two genes were differentially expressed between NASH and SS; most of them correlated with disease severity and related more to cancer progression than to lipid metabolism. Biologically active long‐chain polyunsaturated FAs (PUFAs; eicosapentaenoic acid + docosahexaenoic acid, arachidonic acid) in hepatic total lipids were lower in NASH than in SS. This may be related to overexpression of FADS1, FADS2, and PNPLA3. The degree and direction of correlations between PUFAs and gene expression were different among SS and NASH, which may suggest that low PUFA content in NASH modulates gene expression in a different way compared with SS or, alternatively, that gene expression influences PUFA content differently depending on disease severity (SS versus NASH). Conclusion : Well‐defined subjects with either healthy liver, SS, or NASH showed distinct hepatic gene expression profiles including genes involved in unsaturated FA metabolism. In patients with NASH, hepatic PUFAs were lower and associations with gene expression were different compared to SS. (H epatology 2015;61:1565–1578)

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.27695

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 39

  1. 2010, Pathogenesis of non‐alcoholic fatty liver disease, Q J Med, 103, 71, 10.1093/qjmed/hcp158 · DOI
  2. 2013, Non‐alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches, J Gastroenterol Hepatol, 68
  3. 2005, Hepatic gene expression in patients with obesity‐related non‐alcoholic steatohepatitis, Liver Int, 25, 760, 10.1111/j.1478-3231.2005.01117.x · DOI
  4. 2005, A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease, Hepatology, 42, 665, 10.1002/hep.20838 · DOI
  5. 2011, Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease, Drug Metab Dispos, 39, 1954, 10.1124/dmd.111.040592 · DOI · Paper page
  6. 2010, Role of alcohol metabolism in non‐alcoholic steatohepatitis, PLoS One, 5, e9570, 10.1371/journal.pone.0009570 · DOI
  7. 2012, Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism, PLoS One, 7, e51131, 10.1371/journal.pone.0051131 · DOI
  8. 2014, Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease, Hepatology, 59, 471, 10.1002/hep.26661 · DOI
  9. 2008, Gene expression profiling of non‐alcoholic steatohepatitis using gene set enrichment analysis, Hepatol Res, 38, 1204, 10.1111/j.1872-034X.2008.00399.x · DOI
  10. 2012, Gene expression profiling unravels cancer‐related hepatic molecular signatures in steatohepatitis but not in steatosis, PLoS One, 7, e46584, 10.1371/journal.pone.0046584 · DOI
  11. 2013, Omega‐3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease, Annu Rev Nutr, 33, 231, 10.1146/annurev-nutr-071812-161230 · DOI · Paper page
  12. 2013, Transcriptomic and metabolomic signatures of an n‐3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population, J Nutr Biochem, 24, 54, 10.1016/j.jnutbio.2012.01.016 · DOI
  13. 2008, Nutritional assessment and hepatic fatty acid composition in non‐alcoholic fatty liver disease (NAFLD): a cross‐sectional study, J Hepatol, 48, 300, 10.1016/j.jhep.2007.09.009 · DOI · Paper page
  14. 2004, Increase in long‐chain polyunsaturated fatty acid n‐6/n‐3 ratio in relation to hepatic steatosis in patients with non‐alcoholic fatty liver disease, Clin Sci (Lond), 106, 635, 10.1042/CS20030326 · DOI · Paper page
  15. 2007, A lipidomic analysis of nonalcoholic fatty liver disease, Hepatology, 46, 1081, 10.1002/hep.21763 · DOI · Paper page
  16. 2007, Long term nutritional intake and the risk for non‐alcoholic fatty liver disease (NAFLD): a population based study, J Hepatol, 47, 711, 10.1016/j.jhep.2007.06.020 · DOI
  17. 2014, A cross‐sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls, J Acad Nutr Diet, 114, 1181, 10.1016/j.jand.2014.01.009 · DOI
  18. 2012, Omega‐3 supplementation and non‐alcoholic fatty liver disease: a systematic review and meta‐analysis, J Hepatol, 56, 944, 10.1016/j.jhep.2011.08.018 · DOI · Paper page
  19. 2014, Molecular interplay between delta5/delta6 desaturases and long‐chain fatty acids in the pathogenesis of non‐alcoholic steatohepatitis, Gut, 63, 344, 10.1136/gutjnl-2012-303179 · DOI
  20. 2009, Enhancement in liver SREBP‐1c/PPAR‐alpha ratio and steatosis in obese patients: correlations with insulin resistance and n‐3 long‐chain polyunsaturated fatty acid depletion, Biochim Biophys Acta, 1792, 1080, 10.1016/j.bbadis.2009.08.015 · DOI
  21. 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x · DOI · Paper page
  22. 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  23. 2008, Lumi: a pipeline for processing Illumina microarray, Bioinformatics, 24, 1547, 10.1093/bioinformatics/btn224 · DOI
  24. 2009, Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources, Nat Protoc, 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  25. 2009, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res, 37, 1, 10.1093/nar/gkn923 · DOI · Paper page
  26. 2005, Intrahepatic gene expression profiles and alpha‐smooth muscle actin patterns in hepatitis C virus induced fibrosis, Hepatology, 42, 273, 10.1002/hep.20767 · DOI
  27. 2004, Comprehensive comparison of six microarray technologies, Nucleic Acids Res, 32, e124, 10.1093/nar/gnh123 · DOI
  28. 1957, A simple method for the isolation and purification of total lipids from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
  29. 2006, N‐3 polyunsaturated fatty acids endogenously synthesized in fat‐1 mice are enriched in the mammary gland, Lipids, 41, 35, 10.1007/s11745-006-5067-9 · DOI
  30. 1997, Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study, Diabetes Care, 20, 537, 10.2337/diacare.20.4.537 · DOI · Paper page
  31. 2008, Significant gene expression differences in histologically “normal” liver biopsies: implications for control tissue, Hepatology, 48, 953, 10.1002/hep.22411 · DOI
  32. 2009, Aldo‐keto reductase family 1 member B1 inhibitors: old drugs with new perspectives, Recent Pat Anticancer Drug Discov, 4, 246, 10.2174/157489209789206931 · DOI
  33. 1997, Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18‐month controlled study, J Lipid Res, 38, 2012, 10.1016/S0022-2275(20)37132-7 · DOI
  34. 2010, A common FADS2 promoter polymorphism increases promoter activity and facilitates binding of transcription factor ELK1, J Lipid Res, 51, 182, 10.1194/jlr.M900289-JLR200 · DOI
  35. 2011, Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults, Mol Genet Metab, 103, 171, 10.1016/j.ymgme.2011.02.012 · DOI
  36. 2014, PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans, Diabetologia, 57, 2103, 10.1007/s00125-014-3310-0 · DOI
  37. 2014, The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels, Genes Nutr, 9, 388, 10.1007/s12263-014-0388-4 · DOI
  38. 2014, No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, 377, 10.1053/j.gastro.2014.04.046 · DOI · Paper page
  39. 2013, A self‐directed method for cell‐type identification and separation of gene expression microarrays, PLoS Comput Biol, 9, e1003189, 10.1371/journal.pcbi.1003189 · DOI

Cited by

Sorted by citations

Metadata

Authors
Arendt, B. M., Comelli, E. M., Ma, D. W. L., Lou, W., Teterina, A., Kim, T., Fung, S. K., Wong, D. K. H., McGilvray, I., Fischer, S. E., & Allard, J. P.
Affiliations
  • Toronto General Hospital,University Health Network,Toronto,ON,Canada
  • Department of Nutritional Sciences,University of Toronto,Toronto,ON,Canada
  • Department of Human Health and Nutritional Sciences,University of Guelph,Guelph,ON,Canada
  • Dalla Lana School of Public Health,University of Toronto,Toronto,ON,Canada
  • Department of Computer Sciences,University of Toronto,Toronto,ON,Canada
  • Department of Medicine,University of Toronto,Toronto,ON,Canada
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2015-02-27
Volume
61
Issue
5
Pages
1565-1578
ISSN
  • 0270-9139
  • 1527-3350
DOI
10.1002/hep.27695
Cited by
313
References
2
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 186 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review